# GETUG-AFU 31 (NCT03438552)

> Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence

No report yet. It can be ordered.

- Drugs tested: none (the trial tests no drug)
- Indication: intraprostatic tumor recurrence after external radiation therapy

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03438552
- Phase: NA
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: UNICANCER
- Conditions: Local Recurrence of Malignant Tumor of Prostate
- Interventions: Stereotactic Body Radiotherapy
- Enrollment: 57
- Primary outcome: Selection of the recommended dose for salvage-SBRT (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy) based on dose-limiting toxicity observed during the 18 weeks following the initiation of salvage-SBRT.
- Primary outcome: Estimate the efficacy of the salvage-SBRT in terms of biochemical relapse-free survival rate

## Indexed commentary on GETUG-AFU 31 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 5

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=getug-afu-31-nct03438552